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In Brief
Mucosal surveillance ensures rapid
protection when a pathogen breaches the
barrier. Gilchuk et al. report that local
vaccination elicits a distinct resident
memory CD8+ T cell subset that localizes
to the lung interstitium. These T cells
protect against respiratory infections by
positioning at vulnerable sites and acting
quickly against infections.
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The nature and anatomic location of the protective
memory CD8+ T cell subset induced by intranasal
vaccination remain poorly understood. We devel-
oped a vaccination model to assess the anatomic
location of protective memory CD8+ T cells and their
role in lower airway infections. Memory CD8+ T cells
elicited by local intranasal, but not systemic, vacci-
nation with an engineered non-replicative CD8+
T cell-targeted antigen confer enhanced protection
to a lethal respiratory viral challenge. This protection
depends on a distinct CXCR3LO resident memory
CD8+ T (TRM) cell population that preferentially local-
izes to the pulmonary interstitium. Because they are
positioned close to the mucosa, where infection oc-
curs, interstitial TRM cells act before inflammation
can recruit circulating memory CD8+ T cells into the
lung tissue. This results in a local protective immune
response as early as 1 day post-infection. Hence,
vaccine strategies that induce lung interstitial TRM
cells may confer better protection against respiratory
pathogens.
INTRODUCTION
Memory of past encounters with pathogens is a key feature of
the adaptive immune system and the basis for successful vacci-
nation. Antigen-specific memory CD8+ T cells play key roles in
protection against infectious diseases. A delay in the generation
of effector CD8+ T cells and/or the recall of circulating memory
CD8+ T cells to the site of infection allows pathogens to replicate
and cause disease. Non-circulating tissue-resident memory
CD8+ T (TRM) cells, by virtue of their optimal positioning at bar-1800 Cell Reports 16, 1800–1809, August 16, 2016
This is an open access article under the CC BY-NC-ND license (http://riers (e.g., skin, intestine, female reproductive tract, and respira-
tory tract), keep infections in check at sites of pathogen entry to
confer protective immunity (Ariotti et al., 2012; Bergsbaken and
Bevan, 2015; Bivas-Benita et al., 2013; Hickman et al., 2015;
Jiang et al., 2012; Li et al., 2013; Mackay et al., 2013; Salek-Ar-
dakani et al., 2011; Schenkel et al., 2014; Sheridan et al., 2014;
Shin and Iwasaki, 2012; Sl€utter et al., 2013; Takamura et al.,
2010). Hence, insights into the generation and function of TRM
cells are essential for devising ways to induce protective immu-
nity by vaccination (Clark, 2015; Schenkel and Masopust, 2014).
The respiratory mucosa is a major site for pathogen invasion
and, hence, a site for constant immune surveillance. Safeguard-
ing the lungs (especially the terminal respiratory tree that
consists of alveoli and associated capillary beds) from injury is
critical to preserve lung function. Thus, severe morbidity and
mortality in respiratory infectious diseases are associated with
viral dissemination and inflammation, which can damage the
lung parenchyma and alveoli (Gilchuk et al., 2013; Manicassamy
et al., 2010). To protect from disease, memory CD8+ T cells are
strategically distributed within distinct anatomical compart-
ments of the lungs (Hasenberg et al., 2013; Lelkes et al., 2014;
Rangel-Moreno et al., 2011). The anatomical niche that memory
CD8+ T cells occupy in the lungs depends on the route of infec-
tion (Anderson et al., 2012). Nonetheless, the precise location
and protective capacity of different CD8+ TRM cell subsets in
the lungs that are elicited by vaccination are poorly understood.
Most vaccines in clinical use, including those protecting
against respiratory infections, are administrated to elicit sys-
temic rather than local immune responses. Live and attenuated
microbes are dangerous for use as pulmonary vaccines, and in-
activatedmicrobes poorly elicit cellular immunity. Consequently,
there is a need for physiologically relevant experimental models
that closely recapitulate protective CD8+ TRM cell responses to
vaccination in the lungs. Here, we describe a model in which
lower airway vaccination with a non-replicative pathogen-
derived protein antigen elicits high frequency of epitope-specificcreativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Intranasal Vaccination with CD8+-
Targeted Antigenic Protein and aGC Confers
Enhanced Protection from Respiratory Virus
Infection
Protein antigen was formulated with aGC and
administered to mice by the intraperitoneal or IN
route. Vaccinated mice were challenged with VACV
and assessed for protection.
(A) Design of immunogens used in vaccination.
(B) Prime and boost vaccination approach.
(C) Frequency of epitope-specific CD8+ T cells was
enumerated on day 6 after boost in blood using the
corresponding tetramers. Each symbol indicates an
individual mouse.
(D) Protection of mice that were IP vaccinated with
aGC-formulated L4R or L4R-b8r protein antigens.
(E) Protection of mice that were IP or intranasally
vaccinated with L4R-b8r plus aGC.
(F) VACV burden in the lungs was measured on
days 2, 4, and 6 p.i. in mice vaccinated as in (E);
n = 5–21 mice/group, mean ± SEM; number in-
dicates percent survival based on endpoint criteria.
See also Figure S1.CD8+ TRM cells within the lung tissue that conferred rapid protec-
tion to mice against lethal vaccinia virus (VACV) infection of the
lower respiratory tract. A comparative analysis of the outcomes
of distinct vaccination routes revealed that the protective CD8+
TRM cell subset localized to a spatially distinct niche within the
lung parenchyma and exhibited unique phenotypic features.
RESULTS
Intranasal Vaccination with Antigenic Protein Plus
Adjuvant Confers Enhanced Protection against
Respiratory Virus Infection
We previously reported two HLA-B7.2-restricted VACV-derived
CD8+ T cell epitopes: B8R70–78 (B8R), which elicited a protective
polyclonal CD8+ T cell response upon peptide vaccination; and
L4R37–45, which elicited a robust CD8
+ T cell response but was
non-protective for reasons previously reported (Gilchuk et al.,
2013). This finding was exploited to dissect the protective capa-
bilities of endogenous (non-T cell receptor [TCR] transgenic),
epitope-specific CD8+ T cells. We engineered two recombinantCell ReVACV-derived proteins (L4R and L4R-
b8r). To create L4R-b8r, the native non-
protective L4R37–45 peptide in L4R was
substituted with the protective B8R
epitope. Thus, L4R and L4R-b8r are
made of the same protein scaffold but
differ only in the epitope they contain
(Figure 1A).
To test the immunogenicity of L4R and
L4R-b8r, HLA-B7.2 transgenic (B7.2tg)
mice were primed and boosted intraperi-
toneally (IP) (Figure 1B) with the protein
antigen formulated with a-galactosylcera-
mide (aGC) as the adjuvant (Gilchuk
et al., 2013; Semmling et al., 2010). Stain-ing with the corresponding B7.2-peptide tetramer (Tet) showed
that both protein antigens induced a robust systemic CD8+
T cell response (Figure 1C). The response was specific to the
epitope used for immunization, because the elicited CD8+
T cells reacted only with the cognate tetramer (Figure S1). More-
over, under conditions promoting severe lower airway infection,
intraperitoneal vaccination with L4R-b8r was sufficient to protect
mice from a lethal respiratory VACV challenge, while L4R-vacci-
nated mice succumbed to disease (Figure 1D). Thus, B8R-spe-
cific CD8+ T cells were the sole mediators of protection, with
undetectable contribution by other adaptive immune cells to
the antigen or the adjuvant. We next compared the protective
potential of memory B8R-specific CD8+ T cells generated by
intraperitoneal and intranasal (IN) vaccinations. Strikingly, intra-
nasally vaccinated mice lethally challenged with VACV were
more resistant to disease and showed lower VACV titers in the
lung as early as day 1 post-infection (p.i.) (Figures 1E and 1F).
We concluded that IN vaccination, when compared to intraperi-
toneal vaccination, with CD8+ T cell-targeted antigen more effi-
ciently protected mice from lethal respiratory VACV infection.ports 16, 1800–1809, August 16, 2016 1801
AB
C
D
Figure 2. Epitope-Specific CD8+ T Cells
Participate in Enhanced Protection and
Long-Term Immunity
(A and B) Protection of mice that were treated
intranasally with aGC alone (A) or L4R plus aGC (B)
before lethal challenge with VACV.
(C) Protection of intranasally vaccinated mice that
received 5 mg aCD8 Ab or PBS (mock) intranasally
and challenged 48 hr later with a lethal dose of
VACV. TRM cells were assessed in the lungs of
both groups at 24 hr after the treatment using IV
staining.
(D) Protection of mice that were vaccinated intra-
nasally with L4R-b8R plus aGC and challenged
with VACV on day 50 after boost.
Data are pooled from two or more independent
experiments using n = 3 ormoremice/group (A and
B). One of two independent experiments for (C)
and (D), n = 3–14 mice/group; mean ± SEM.
Number indicates percent survival based on
endpoint criteria. See also Figure S2.Epitope-Specific CD8+ T Cells Elicited by Protein
Vaccination Mediate Long-Term Protection against
Lethal Virus Infection
IN aGC administration rapidly induces local inflammatory re-
sponses and interferon-g (IFN-g) production (Courtney et al.,
2011), potentially explaining the enhanced protection observed
when aGCwas used as an adjuvant. To investigate antigen spec-
ificity of the observed protective immune responses, we primed
and boosted mice intranasally with aGC alone or with aGC plus
L4R-b8r and then challenged them with VACV on day 14 or on
day 24 after boost. We chose day 24 after boost because aGC-
induced IFN-g responses in the lungs wane substantially by
then (Courtney et al., 2011). We found that IN aGC treatment
14 days before challenge played very little role in conferring pro-
tective immunity that waned after 3 weeks. (Figures 2A, 2B, S2A,
andS2B). Thus,B8R-specificCD8+Tcells in the lungsparticipate
in enhanced protection to respiratory infection.
To directly demonstrate that CD8+ T cells elicited upon IN
vaccination participated in protection, we locally depleted
them by IN aCD8 antibody (Ab) delivery (Sl€utter et al., 2013).
Lung TRM cells were quantified after intravascular (IV) staining
with aCD45 Ab in vivo to identify circulating blood leucocytes
(Anderson et al., 2014). Local CD8+ T cell depletion significantly
decreased the number of CD8+ TRM cells in the lungs (Tet+
aCD45 Ab) but maintained intravascular CD8+ T cells (Tet+1802 Cell Reports 16, 1800–1809, August 16, 2016aCD45 Ab+; Figures 2C and S2C–S2E).
This depletion rendered otherwise resis-
tant intranasally vaccinated mice more
susceptible to respiratory VACV chal-
lenge (Figures 2C and S2C–S2E),
showing that lung TRM cells participate in
protection.
Finally, we investigated the duration of
protection by memory CD8+ T cells eli-
cited after intraperitoneal or IN vaccina-
tion. Notably, only intranasally vaccinated
and not IP-vaccinated mice were pro-tected when challenged intranasally with VACV at day 50 after
boost, suggesting a key role for IN vaccination in establish-
ing long-lasting protective immunity (Figure 2D). These data
together established a non-TCR transgenic mouse model to
study the basis of immune protection rendered against lethal
respiratory infection by endogenous lung CD8+ TRM cells.
Intranasal Vaccination Elicits a Distinct CXCR3LO CD8+
TRM Cell Subset in the Lung Interstitium
We next investigated the immunologic properties of B8R-spe-
cific CD8+ T cells elicited by intraperitoneal or IN vaccination.
We found that both immunization routes elicited robust systemic
and local pulmonary memory CD8+ T cell responses of compa-
rable frequency (Figure 3A). B8R-specific CD8+ T cells elicited
by both vaccination routes responded to antigen by producing
IFN-g and mobilizing CD107a to the cell surface (Figures S3A
and S3B). Upon IN VACV challenge, a higher frequency of re-
sponding B8R-specific CD8+ T cells was found in the lungs of
IP-vaccinated mice when compared to those of intranasally
vaccinated mice (Figures S3C and S3D). Hence, the frequency
of antigen-specific CD8+ T cells capable of producing IFN-g
and degranulate fail to explain why IN vaccination enhances pro-
tective immunity.
The airways and the lung parenchyma are composed of
specialized immunological niches (Hasenberg et al., 2013)
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Figure 3. IN Vaccination Elicits Distinct
CXCR3LO CD8+ TRM Cells that Are Enriched
in the Lung Interstitium
(A) B8R-specific CD8+ T cell frequency enumer-
ated in blood days 4–6 after boost, or in lungs on
days 7–10 after boost.
(B and C) Partitioning (B) and ratio (C) of memory
CD8+ T cells in the lung parenchyma and BAL of
IP- or intranasally vaccinated mice assessed by
in vivo staining by intravenous aCD45 Ab delivery
followed by ex vivo tetramer staining. Plots are
gated on viable CD8+ T cells; the arrow indicates
interstitial TRM (Tet+ IV aCD45 Ab) that are en-
riched in the lung parenchyma of intranasally
vaccinated mice.
(D) Phenotype of resting (days 14–24 after IN
boost) or VACV-activated B8R-specific lung CD8+
T cells assessed after IV staining. Resting AW TRM
cells were assessed only for CXCR3 due to their
low number. Data are pooled from three or more
independent experiments using n = 3 or more
mice/group and represented as mean ± SEM.
See also Figures S3 and S4.suggesting that local versus systemic vaccination results in dif-
ferential localization of memory CD8+ T cells within the lungs.
By staining with aCD45 Ab in vivo and with aCD8 Ab and
Tet ex vivo, the distribution of airway (AW)-resident CD8+
T cells in bronchoalveolar lavage (BAL) and parenchymal
CD8+ T cells in two anatomically distinct compartments of
the lungs (the vasculature [‘‘marginated’’ vascular (MV)] and in-
terstitium [interstitial (IST)]) were assessed in response to the
two immunization routes. We found that the Tet+ aCD45 Ab
CD8+ T cells of the BAL and lung parenchyma were attributed
to AW and IST TRM cells, respectively (Figure 3B), as previously
suggested by others (Anderson et al., 2014; Barletta et al.,
2012).
Most B8R-specific CD8+ T cells (>95%), after intraperitoneal
immunization but prior to challenge were Tet+ aCD45 Ab+ repre-
senting the MV memory pool confined to the lung vasculature
(Figures 3B and 3C). In contrast, after IN immunization, B8R-spe-Cell Repcific CD8+ T cells were located within
the lung interstitium (Tet+ aCD45 Ab),
vasculature (Tet+ aCD45 Ab+), and air-
ways (Tet+ aCD45 Ab). Remarkably,
IST TRM cells comprised a large fraction
(>50%) and AW TRM cells represented
only a minor fraction (<2%) of total mem-
ory CD8+ T cells in the lungs (Figures 3B
and 3C). Thus, local antigen exposure
and inflammation are critical for gener-
ating and maintaining a high frequency
of IST TRM cells in the lungs.
The frequency of MV and IST CD8+
T cells in perfused lungs was >3- to 10-
fold higher than in the blood or lung-asso-
ciated lymph nodes (LNs) (Figures S4A
and S4B). Hence, the MV and IST mem-
ory CD8+ T cells detected in this studywere confined to lung parenchyma and were not blood or LN
contaminants. Tet+ aCD45 Ab TRM cells recovered from the
BAL uniformly expressed CXCR3HI, a marker for AW TRM cells
(Kohlmeier et al., 2009; Sl€utter et al., 2013). In contrast, Tet+
aCD45 Ab TRM cells retained in the lung parenchyma after
perfusion were CXCR3LO, suggesting no cross-contamination
between AW and IST TRM cells (Figure S4C).
Resting IST TRM cells were composed of CD103HI and
CD103LO/NEG subsets that expressed higher levels of CD69
and CD44 than MV CD8+ T cells and were KLRG1LO, CD62LLO,
CCR7LO, CD122LO, and CD127HI, a phenotype consistent with
the current definition of a TRM cell (Figure 3D). Unlike CXCR3HI
AW TRM cells, IST TRM cells were CXCR3LO, thereby discrimi-
nating between the two TRM cell subsets in the lungs (Figures
3D and S4C). Resting and activated IST TRM cells were
responsive to re-stimulation with antigenic peptide and stained
for GzmB ex vivo (Figure 3D; data not shown). Thus, INorts 16, 1800–1809, August 16, 2016 1803
immunization with a non-replicative immunogen and aGC
elicited functionally competent and CXCR3LO memory CD8+
T cells that occupied a distinct anatomical niche in immune lungs
and acquired a tissue resident phenotype.
IST TRM Cells Persist in the Lungs and Respond before
SystemicMemory CD8+ T Cells Are Recruited to the Site
of Infection
We next determined the prevalence of B8R-specific CD8+ T cells
within the lung parenchyma and BAL after intraperitoneal or IN
vaccination and during infection (Figure 4A). Regardless of the
vaccination route, similar numbers of MV Tet+ CD8+ T cells
were detected in the lungs at day 14 post-boost and until day
4 after lethal IN VACV challenge. Strikingly, at the same time
points therewere15- to 40-fold higher numbers of IST TRM cells
in intranasally vaccinated lungs as compared to IP-immunized
lungs (Figure 4A). Moreover, IN vaccination established 3 3
104 IST TRM cells per lung, which accounted for >98% of total
lung CD8+ TRM cells during early infection. This IST TRM cell num-
ber is likely an underestimate, owing to dramatic cell losses
(>98%) incurred during tissue processing (Steinert et al., 2015).
IN immunization also induced 500 AW CD8+ TRM cells per
lung, which were undetectable in IP-immunized mouse lungs
(Figure 4A). This small population of AW TRM cells was sustained
in the airways without substantial change in number until day
6 p.i. The dramatically higher number of pre-existing IST TRM
cells present during early infection was associated with the
rapid reduction of viral load in intranasally vaccinated mice.
Conversely, the delayed accumulation of IP-induced memory
CD8+ T cells in the lung tissue was consistent with the increased
VACV burden in these mice (Figure 1F).
Efficient CD8+ T cell-mediated immune surveillance in infected
tissues requires a high density of responders (Halle et al., 2016),
with an estimate of3,000 TRM cells per million nucleated cells in
the lungs (Steinert et al., 2015). Hence, we hypothesized that the
highly abundant IST TRM cells, in comparison to 500 AW TRM
cells, participated in the rapid control of the infection established
with 105 PFU VACV that spreads through 2 3 106 alveoli. To
test this hypothesis, we attempted adoptive transfer or selective
local depletion of AWor IST TRM cells before VACV challenge.We
could not repopulate the lungs with a physiological density of
endogenous epitope-specific IST TRM cells because of poor
yields (Steinert et al., 2015) and poor homing efficiency (data
not shown). IN application of aCD8 Ab depleted AW TRM cells
as expected (Sl€utter et al., 2013), but significantly reduced IST
TRM as well (Figures S2C–S2E). As an alternative approach, we
repopulated the airways of IP-vaccinated mice with 770 B8R-
specific AW TRM cells per lung, which approximates two times
their physiological number, harvested from intranasally vacci-
nated and VACV-challenged mice. The transferred AW TRM cells
neither egressed into the lung parenchyma nor provided resis-
tance to VACV infection (Figure S5). Together these data suggest
that IST TRM cells elicited by IN, but not intraperitoneal, vaccina-
tion conferred early virus control and enhanced protection.
To determine why the pre-existing systemic memory CD8+
T cells accumulated slowly in the infected lungs, we assessed
their proliferation kinetics. For this, IP-vaccinated mice were
intranasally challenged with VACV and then pulsed with EdU1804 Cell Reports 16, 1800–1809, August 16, 2016(5-ethynyl-20-deoxyuridine) for 1 day. B8R-specific AW and IST
TRM cells showed modest EdU incorporation by day 4 p.i. and
profound incorporation by day 6 p.i. By contrast, proliferation
of B8R-specific blood, splenic, and lung MV CD8+ T cells was
obvious only by day 6 p.i. (Figure 4B). Although it is likely that
memory CD8+ T cells were proliferating in the draining LN at
this time point (Moyron-Quiroz et al., 2006), proliferating cells
were not detected in the blood and spleen until day 6 p.i. This
result suggested that systemic CD8+ T cells had not yet left the
LN to participate in viral clearance. The increased total number
of B8R-specific IST TRM cells in the lungs observed on day 4
p.i. was inversely related to 3- to 8-fold lower B8R-specific
CD8+ T cells in blood, spleen, and lung vasculature (Figure 4C).
Thus, the delayed recruitment of systemic resting memory CD8+
T cells to the lungs accounted for late accumulation of IST and
AWTRM cells during infection, which then extensively proliferated
in situ.
By virtue of their location, IST TRM cells can quickly engage in
contact-dependent killing of infected lung tissue to confer
enhanced immune protection, whereas MV CD8+ T cells are
spatially isolated and cannot do so. To assess early activation
of CD8+ T cell subsets in the lungs, intranasally immunized
mice were challenged with VACV, and B8R epitope-specific
MV CD8+ T cells (mostly CD69LO) and IST TRM (mostly CD69HI)
were assessed for CD69 induction within 36 hr p.i. Remarkably,
only IST TRM cells and not MV CD8+ T cells upregulated CD69
expression (Figure 4D), suggesting that IST TRM cells are key
initial responders to infection.
Interstitial TRM Localize to Sites of the Lungs that Are
Vulnerable to Infection
We previously showed that mortality in naive VACV-challenged
mice was due to severe damage of alveoli characterized by
widespread necrosis and fibrin-filled and edematous alveolar
spaces (Gilchuk et al., 2013). Here, we determined the sites of
VACV infection following IN inoculation with GFP reporter virus
(Norbury et al., 2002) in conjunction with fluorescent labeling of
type I alveolar epithelial cells with anti-rodoplanin Ab (Vanderbilt
et al., 2008) on day 4 p.i. Confocal microscopy revealed that
VACV localized to two spatially distinct niches surrounding the
bronchioles and type I epithelial cells that form the alveolar walls
(Figure 5A). Accordingly, imaging of aCD45 Ab CD8+ T cells in
acutely infected lungs of vaccinated mice showed localization to
the sites that are vulnerable to VACV infection, including the
bronchioles and alveolar walls (Figure 5B).
Imaging of endogenous antigen-specific CD8+ T cells in the
lungs was reported previously (Khanna et al., 2008; Moyron-
Quiroz et al., 2006), but whether CD8+ TRM cells occupy niches
in the lung parenchyma where fatal infection occurs remains un-
known. The pulmonary interstitium is the support tissue within
the lungs; it includes the alveolar epithelium, capillary bed endo-
thelium, basementmembrane, and the perivascular and perilym-
phatic tissues. Collectively, they constitute the walls of the bron-
chioles and alveoli. To determine the location of VACV-specific
IST TRM cells, we stained thick fresh lung sections with fluores-
cent B8R tetramer (red) after IV labeling of vascular leucocytes
with aCD45 Ab (blue) and vascular endothelium of alveolar capil-
lary beds with fluorescent tomato lectin (green). Using selective
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Figure 4. IST TRM Cells Persist in the Lungs and Respond before Systemic Memory CD8+ T Cells Accumulate to the Site of Infection
(A) Counts of B8R-specific MV, IST, and AWCD8+ T cells that were determined after intraperitoneal or IN vaccination (day 0) and at the indicated time points after
IN challenge with VACV (n = 3–12 mice/group, mean ± SEM).
(B) Proliferation kinetics of splenic, blood, and lung B8R-specific CD8+ T cells of IP-vaccinated mice was assessed by EdU incorporation at indicated time points
p.i. Representative of three or four mice per group per time point.
(legend continued on next page)
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plane illumination microscopy (SPIM), we achieved volumetric
imaging that allowed visualization of VACV-specific CD8+
T cells in the alveolar interstitium (IST TRM, red) and alveolar capil-
lary beds (MV CD8+ T cells, magenta from the merge of red and
blue) (see Figure 5C). We found that IN vaccination induced a
substantial number of IST TRM cells that localized within the alve-
olar walls, outside of alveolar capillaries (Figure 5C). Such a loca-
tion of IST TRM cells was evenmore prominent in acutely infected
lungs of intranasally vaccinated mice, showing that infected
alveoli are common sites of immune surveillance by IST TRM cells
that are located at the most vulnerable sites within the lung
parenchyma.
DISCUSSION
At the internal barriers, the mucosal immune response confers
the first line of defense against invading pathogens. Here, we
report a distinct protective CD8+ TRM cell that is elicited by IN
protein antigen plus adjuvant vaccination and localized to the
lungs interstitium, an anatomical site intimately connected to
the respiratory mucosa. Sublethal respiratory infections induce
bronchus-associated lymphoid tissue that serves as a site for
naive CD8+ T cell priming and a niche for TRM cell maintenance
(Halle et al., 2009). Accordingly, IN infection with live influenza
virus elicited a robust TRM cell response that localized mostly
around the large airways and blood vessels of the lungs (Wu
et al., 2014). Other studies have suggested a protective role
for CXCR3HI memory CD8+ T cells also induced by viral infec-
tion but located within the airway lumen (McMaster et al.,
2015; Sl€utter et al., 2013). Our findings extend the types of pro-
tective TRM cells that patrol the lungs. Thus, in our IN protein
antigen plus aGC adjuvant vaccination model, we identified a
major CXCR3LO IST TRM cell subset that localizes to the most
vulnerable sites of infection—the alveolar and bronchiolar walls.
Efficient CD8+ T cell-mediated tissue surveillance depends on
high responder density (Halle et al., 2016; Steinert et al.,
2015). Accordingly, upon IN vaccination, IST TRM cells were eli-
cited at physiologically relevant numbers and accounted for
most of the lung TRM cells, suggesting these TRM cells are key
initial responders to infection. Nonetheless, at the late stages
of infection, we do not discount the possibility that IST TRM cells
may replenish AW TRM cells, which together with systemic
effector memory CD8+ T cells may substantially contribute to
the resolution of infection.
The mechanism by which CXCR3LO IST TRM cells are recruited
and preferentially retained in the lung interstitium upon vaccina-
tion remains unclear. In this regard, our preliminary transcrip-
tome analysis of naive lung CD8+ T cells and purified IST TRM
cells revealed many differentially expressed genes that could
be associated with trafficking and/or residence in non-lymphoid
tissues, including CCR7, Itgae, Cxcr6, Cxcr3, Klrg1, Klf2, and(C) Number of Tet+ CD8+ T cells in spleen, blood, and lungs of mice vaccinated an
mean ± SEM).
(D) Intranasally vaccinatedmice were challenged with VACV or mock-inoculated w
were assessed for CD69 induction from pooled lungs in each group.
See also Figure S5.
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in IST TRM cell recruitment, retention, and function awaits further
study.
Devising vaccination strategies to elicit TRM cells in barrier tis-
sues by immunization through an accessible tissue, such as skin,
is an important goal for human vaccine design (Park and Kupper,
2015). In this regard, it is noteworthy that vaccination with VACV
or replication-deficient modified vaccinia virus Ankara by skin
scarification elicited memory CD8+ T cells that protected mice
from lethal respiratory infection, although inactivated viruses
failed to do so (Liu et al., 2010). Local immunization with CD8+
T cell-targeted epitope plus adjuvant could be a promising alter-
native to distal vaccination approach that uses virus vectors.
Future studies will determine if vaccination by skin scarification
with subunit vaccine formulation have the potential to elicit pro-
tective TRM cells that also localize to distal barrier tissues. We
hope our findings will have implications for the design of safe
and effective CD8+ T cell-targeted vaccines against respiratory
infections.
EXPERIMENTAL PROCEDURES
Mice, Viruses, and Antigens
B6-K0D0;B*07;02tg (B7tg) transgenic mice have been described elsewhere
(Alexander et al., 2003). Mouse breeding, maintenance, and experimentation
complied with institutional animal care and use committee (IACUC)
regulations.
The Western Reserve strain of VACV and VACV-GFP (a gift from J.W. Yew-
dell) were grown in and titrated with BSC-40 cells.
The design of recombinant L4R-derived antigen has been described
elsewhere (Gilchuk et al., 2013). L4R-b8r DNA was generated by substituting
the sequence that encodes FPRSMLSIF (L4R37–45) in L4R33–249 DNA with a
sequence that encodes FPKNDFVSF (B8R70–78). Recombinant antigens
were purified to high purity as described previously (Gilchuk et al., 2013).
Vaccination, Infections, and Burden
Ketamine-xylazine-anesthetized, 6- to 8-week-old mice were inoculated intra-
nasally or intraperitoneally twice with 50 mg antigenic protein formulated with
1 mg aGC (Funakoshi) in 100 ml PBS. To challenge, anesthetized mice were
inoculated with 105 PFU VACV in 50 ml PBS. Mice were monitored daily for
morbidity, and those losing over 30% of initial body weight were euthanized
per IACUC regulations.
Lungs from individual mice were washed with PBS, homogenized, and sub-
jected to one freeze/thaw cycle, and serial 10-fold dilutions were plated on
confluent BSC-40 cells. Plaques were visualized by crystal violet staining.
IV Staining and Flow Cytometry
IV staining was performed with fluorescently labeled aCD45 Ab as described
previously (Anderson et al., 2014) but modified to precisely discriminate MV,
AW, and IST CD8+ T cells. After IV staining, lungs were perfused, which re-
moves cells from the vasculature and airway lumen while retaining MV and
IST CD8+ T cells within the lung parenchyma. To account for BAL CD8+
T cells, the backflow from the airways, typically generated upon perfusion,
was quantitatively recovered as detailed in the Supplemental Experimental
Procedures.d challenged as in (B) was assessed at the indicated times (n = 3–4 mice/group,
ith PBS (n = 4–5mice/group). 36 hr p.i., Tet+ MVCD8+ T cells and IST TRM cells
AB
C
(legend on next page)
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In Vivo CD8+ T Cell Proliferation
Mice were injected with 1 mg EdU (Life Technologies) IP 24 hr before analysis.
After IV staining, lung cells were labeled with viability dye to discriminate dead
cells, followed by staining with tetramer and Abs. Cells were stainedwith Click-
iT Plus EdU Alexa488 (Life Technologies) according to the manufacturer’s
protocol.
Confocal Microscopy and SPIM
For imaging of VACV-GFP, 10 mm fresh-frozen lung sections were stained with
aGFP-Alexa Fluor 488-conjugated Ab and mouse rodoplanin Ab followed by
secondary Alexa Fluor 647-conjugated Ab. For imaging of CD8+ T cells, lungs
were harvested after IV staining with aCD45-BV421 Ab and fixed with 4%
paraformaldehyde (PFA). Frozen 10 mm sections were stained with aCD8+-
PE Ab and AF488-labeled tomato lectin (Vector Laboratories). Confocal micro-
scopy was performed using an AxioObserverZ.1 inverted microscope (Zeiss)
equipped with a 203 1.0 numerical aperture (NA) objective; 405-nm,
488-nm, and 561-nm laser lines; and dual sCMOS cameras. Image analysis
was performed with Imaris software (Bitplane Scientific). For imaging of
B8R-specific CD8+ T cells in the lungs, mice were intravenously (i.v.) injected
with AF488-labeled tomato lectin and aCD45-BV421 Ab, which visualizes
vasculature and vascular leukocytes, respectively. Fresh, 1-mm-thick sections
were cut with tissue slicer followed by overnight incubation with B8R tetramer-
PE. Washed tissues were mounted in 1% agarose and analyzed using the
LightsheetZ.1 platform (Zeiss) equipped with a CSU-22 spinning disc (Yoka-
gawa), 473-nm and 660-nm laser lines, a 20 0.75 NA Plan-Apo objective,
and an Evolve EMCCD camera (Photometrics). Images were analyzed using
Slidebook software (Intelligent Imaging Innovations).
Statistics
Descriptive statistics (mean ± SEM or mean ± SD) are provided for continuous
variables as noted. The Wilcoxon rank-sum test or two-sample t test was
applied to two-group comparisons or the post hoc group comparisons in
ANOVA; all tests were two tailed and unpaired (*p < 0.05; **p < 0.01; ***p <
0.001; ns, not significant). Statistical analyses were performed using the
open source R software (version 2.15).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.07.037.
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